Illumina price target raised to $130-$135 from $90-$95 at Wells Fargo Wells Fargo increased its price target on Illumina after the company provided higher than expected 2014 revenue guidance and introduced two new systems. The firm believes that the company's position in the high-throughput sequencing and low/mid-throughput market has been enhanced. It keeps an Outperform rating on the shares.
News For ILMN From The Last 14 Days
Check below for free stories on ILMN the last two weeks.
WuXi PharmaTech purchases Illumina HiSeq X Ten Sequencing System Illumina (LMN) and WuXi PharmaTech (WX) announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system. This new investment will enable WuXi’s clinical genomic services to expand from the current target panel, exome, and transcriptome scale sequencing to population genome scale sequencing. It puts the world’s most advanced gene sequencing capability in the hands of the leading pharmaceutical R&D services company in the Asia Pacific region. The WuXi Genome Center meets international clinical standards and is the only CLIA-certified clinical genomics lab in China. In addition to offering sequencing services, WuXi’s genomics lab also provides assay development, validation, and testing services.